Section 10400.4 - Lincoln Staphage Lysate Agent for Treatment of Cancer(a) As used in this section, Lincoln Staphage Lysate means that agent described and defined in the report entitled REPORT, FINDINGS AND RECOMMENDATIONS of the CALIFORNIA CANCER ADVISORY COUNCIL to DIRECTOR, CALIFORNIA STATE DEPARTMENT OF PUBLIC HEALTH, 2151 Berkeley Way, Berkeley 4, California, with respect to THE TREATMENT OF CANCER WITH LINCOLN STAPHAGE LYSATE, dated April 17, 1963, which agent consists of staphylococcus bacteriophage lysates, alpha and beta is commonly known as Lincoln Staphage Lysate.(b) Except as otherwise provided in Section 1708 of the Health and Safety Code the prescription, administration, sale or other distribution of Lincoln Staphage Lysate, as defined in subsection (a) of this section, or any agent substantially similar thereto, in the diagnosis, alleviation, treatment or cure of cancer, or for the treatment of any patient who has or who believes that he or she has or who may have cancer is prohibited.(c) No person shall, for the purpose of prescribing, administering, selling or otherwise distributing Lincoln Staphage Lysate, make any representation that it has any value in arresting, alleviating or curing cancer.Cal. Code Regs. Tit. 17, § 10400.4
1. New section filed 10-3-63; effective thirtieth day thereafter (Register 63, No. 17).
2. Amendment filed 12-17-85; effective thirtieth day thereafter (Register 85, No. 51). Note: Authority cited: Sections 208 and 1704, Health and Safety Code. Reference: Section 1704, Health and Safety Code.
1. New section filed 10-3-63; effective thirtieth day thereafter (Register 63, No. 17).
2. Amendment filed 12-17-85; effective thirtieth day thereafter (Register 85, No. 51).